Press release
Number of voting right and shares as of January 31, 2017
02 Feb 2017 18:40 CET
Company Name
FR0004032746-ALXP
ISIN
FR0004032746
Total number of voting rights and shares
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority).
Date |
Total number of shares |
Number of existing voting rights (GROSS) |
Number of existing voting rights (NET) |
01/31/2017 |
45,155,511 |
46,797,879 |
42,287,047 |
“Including 660,000 new shares in accordance with the contract of Equity line financing concluded with Kepler Cheuvreux on November 20th 2014, for a total amount of 559,400€. A shareholder holding 1.0% of the Company share capital (December 31st, 2016) would be reduced to approximately 0,99% of the capital on non-diluted basis”
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
Connect_neovacs_regulated-information-reglementee31012017.pdf